» Biomarin

Making connections in Morquio A.

For the past 80 years, physicians and patients believed Morquio A (MPS IVA) was primarily a skeletal condition. But recent research has shown that the disease—resulting from a deficiency of a critical enzyme—causes severe, progressive damage to multiple organ systems. What’s the best way to bring these powerful new insights to life—and to clinical practice?

Together with BioMarin, we created numerous points of contact—online and offline—to help reinforce evolving understanding of Morquio A for patients, families, physicians, and payors. Morquiosity.com brings a completely new level of information and empathy to people and families facing the challenges of Morquio A. Using social interactivity, groundbreaking user experience, and long-scroll design, the site’s architecture allows for easy navigation and on-demand access to in-depth disease education and management resources never before available to the Morquio A community—all in one place.

Real patient images celebrate the strength—and achievements—of people with Morquio A, while the language of the site accurately describes the clinical effects of the condition in an accessible, conversational style guided by the principles of health literacy.
Using interactive social functionality built into the site, people with Morquio A can literally put themselves on the map and share their stories, showing diversity and strength, and opening up the possibility for even closer relationships within the community.

Rollovers for clinicians on MorquioAnswers.com (a physician property) reveal that each patient faces unique challenges—but all share the potential threat of systemic morbidities and challenges of disease management.

Developed closely with PhD-level clinical strategists at CB, a comprehensive mechanism of disease animation helps elucidate new clinical understanding of molecular pathologic sequelae and far-reaching impact on patient outcomes.
These groundbreaking Morquio A resources demonstrate the deep BioMarin commitment to this unique rare disease community—and to powerful, innovative communications that can truly make a difference in patient health.